Penpulimab Clinical Trials

4 actively recruiting trials

Also known as: PD-1 monoclonal antibody

Pipeline

Phase 2: 3Phase 1/2: 1

Top Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
Ruijin Hospital1
Fudan University1
Akeso1

Indications

Cancer4
Non-small Cell Lung Cancer Stage IIIB/IV1
Pancreatic Adenocarcinoma Metastatic1
Colorectal Adenocarcinoma1
Locally Advanced1

Other4 trials

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1/2

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Phase 2

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Phase 2

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.